Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

Inclusion Criteria:

1. Men, and women, over 18 years of age inclusively.

2. Patient is suspected to have COVID-19 infection.

3. Provides consent or consent is given by their legally authorized representative (LAR).

4. Agrees to the collection of venous blood per protocol.

5. Women of childbearing potential (WOCBP) and men (if their sexual partners are WOCBP)must use at least 1 highly effective form of birth control throughout the study andfor 6 months after the last dose of study treatment. Highly effective methods ofbirth control include true sexual abstinence (defined as refraining fromheterosexual intercourse during the entire period of risk, in line with thepreferred and usual lifestyle of the patient), surgery (bilateral tubal ligation orocclusion, vasectomized partner), progestogen-only or estrogen/progestogen hormonalcontraceptive associated with inhibition of ovulation (oral, patch, injectable,implantable, or intravaginal), intrauterine device (IUD), or intrauterinehormone-releasing system (IUS).

Exclusion Criteria:

1. Pregnancy, lactation and those who are not pregnant but do not take effectivecontraceptive measures, in women of childbearing age. Absence of pregnancy will beconfirmed through urine pregnancy test.

2. Patients who have participated or are participating in a clinical trial of anexperimental vaccine for SARS-CoV-2 or coronavirus during the study or within 30days.

3. Inability to provide informed consent or to comply with study requirements.

4. Patients with the following concomitant or past medical history:

• Both Hypertension and Diabetes Mellitus.

• Both Hypertension and Chronic Kidney Disease.

• Both Diabetes Mellitus and Chronic Kidney Disease.

5. History or evidence of alcohol abuse.

6. History or evidence of consumption of illicit drugs.

7. Patients requiring mechanical ventilation.

8. Patients who are determined by the Principal Investigator to be unsuitable for studyenrollment for other reasons.

9. Any medical disease or condition that, in the opinion of the site PrincipalInvestigator or sub-investigator, precludes study participation. Including acute,subacute, intermittent or chronic medical disease or condition that would place thesubject at an unacceptable risk of injury, render the subject unable to meet therequirements of the protocol, or may interfere with the evaluation of responses orthe subject's successful completion of this trial.